Naveris Raises $51M for Early Detection of Viral-Driven Cancers
Naveris, a life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers raises $55M.
Stay updated with breaking news from Techu Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Naveris, a life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers raises $55M.
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.
Arpeggio Biosciences raised $17 million in a Series A funding round led by Builders VC. The startup is focused on measuring the transcriptome — which refers to the full range of mRNA molecules expressed by an organism — to develop better therapeutics.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!